CARE-NMD (3 years; M€1.6; 6513 person/days) aims to optimize the treatment of Duchenne muscular dystrophy (DMD)in participating countries and by that to improve the quality of life for patients.
Specific objectives are:
-> Identify the status of DMD treatment approaches in targeted countries by (online)- questionnaires by month 24, response rate will be the measure.
-> According to the results of questionnaires obtained, training sessions will be organised at national levels with healthcare providers to support compliance of healthcare practices with the recommended and established SoC over the full 36month. Measured by number of participants and number of workshops organised in each targeted country.
-> Popularize the CARE-NMD project, measured by CARE-NMD Website visits and registration rate in national patient registries and care and trial Site registry
-> Increase awareness and knowledge about treatment recommendations, measured by amount of input online discussion forum and amount of national multidisciplinary training workshops.





EuroNeoStat II mission or strategic goal is that all Very Low Gestation (VLGA, gestation <32 wks) and Very Low Birth Weight (VLBW, birthweight <1501 g) infant born in Europe, receive the best possible health care no matter where born by preventing existing inequalities and that all Neonatal Units use the indicators developed, to assess the quality of care provided and implement strategies to improve outcome.


This Joint Action aims to enable coordinated pharmacovigilance operations in the EU network, making best use of worksharing and resources. A key aim is to help lower-resourced Member States develop skills and capacity in pharmacovigilance network to benefit citizens in their territory and the whole network. The Joint Action will help ensure a consistent approach across all member states for collecting information on adverse drug reactions; identifying safety issues; communicating risk and assessing risk minimisation measures all within the operation a standardised quality management system. This will benefit medicines safety monitoring and communications outputs and thereby help to safeguard public health.




The project aims to develop urgently needed supplements to the current EU guidelines in order to take into account new developments and improve prevention of cervical cancer through HPV vaccination and testing.
